| __timestamp | Amicus Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 1499100000 |
| Thursday, January 1, 2015 | 47269000 | 1923500000 |
| Friday, January 1, 2016 | 71151000 | 2351400000 |
| Sunday, January 1, 2017 | 88671000 | 2564000000 |
| Monday, January 1, 2018 | 127200000 | 2397300000 |
| Tuesday, January 1, 2019 | 169861000 | 2503400000 |
| Wednesday, January 1, 2020 | 156407000 | 3344600000 |
| Friday, January 1, 2021 | 192710000 | 4529200000 |
| Saturday, January 1, 2022 | 213041000 | 4179100000 |
| Sunday, January 1, 2023 | 275270000 | 4650100000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Amicus Therapeutics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Amicus Therapeutics in SG&A spending, with expenses peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, Amicus Therapeutics saw a more modest rise, with expenses growing by about 1,230% to reach $275 million in 2023. This disparity highlights Viatris's expansive operational scale compared to Amicus's more focused approach. Such insights are invaluable for investors and industry analysts seeking to understand the strategic priorities and market positioning of these pharmaceutical giants.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.